This release corrects and replaces the previous release editing the date of the Quarter Ending March 30 to March 31, 2022.

cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the world's leading, and most highly trusted and recognized health & wellness CBD companies, announced today that it will host a conference call at 4:30 p.m., Eastern Time, on Friday, May 13, 2022, to discuss the company's March 31, 2022 second quarter financial results and business progress.

CONFERENCE CALL DETAILS

Friday, May 13, 2022, 4:30 p.m. Eastern Time

USA/Canada:

800-319-4610

International:

604-638-5340

Teleconference Replay dial in:

USA/Canada:

855-669-9658

International:

412-317-0088

Replay Passcode:

8972

Webcast/Webcast Replay link- available through May 13, 2023: https://www.gowebcasting.com/11834

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products as well as our new Full Spectrum products. Our cbdMD brand currently includes over 130 SKU's of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes. Our Paw CBD brand of pet products includes over 45 SKUs of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our CBD Botanicals brand of beauty and skincare products features 15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. To learn more about cbdMD and their comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to the expansion of the consumer market for CBD products and our ability to increase our market share, our limited operating history, our ability to expand our business and significantly increase our revenues, our ability to effectively leverage our brand partnerships and sponsorships, our ability to effectively compete in our market, our ability to achieve our net sales guidance, and our ability to report profitable operations in the future. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the 'SEC') and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

1 ​THC-free is defined as below the level of detection using validated scientific analytical tools.

Contacts :

Investors:cbdMD, Inc.John WestonDirector of Investor Relations[email protected] (704) 249-9515

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123135

Original Source of the original story >> CORRECTION FROM SOURCE: cbdMD, Inc. to Host Conference Call to Discuss March 31, 2022, Second Quarter Results

This content is published on behalf of the above source. Please contact them directly for any concern related to the above.